| Public policy trends in drug pricing and reimbursement in the European Community. | |
| | |
MedLine Citation:
|
PMID: 10172481 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
In the European Community, the key issue of cost containment in healthcare (including pharmaceuticals) is dominated by three main background influences: The principle of 'solidarity' (society's responsibility for those who cannot afford to pay the full cost of healthcare); 'subsidiarity' (doing nationally what is best done nationally rather than at the Community level); and the 'pharmapolitics' of balancing the drug budget with the demands of patients in their capacity as voters. Pharmaceutical expenditure generally exceeded the rate of inflation during the 1980s despite legislation to contain costs. In the 1990s, more intensive efforts are being applied to oblige doctors to prescribe rationally and economically whilst putting even greater pressure on the pharmaceutical industry. Again with an eye on electoral repercussions, only limited attempts to make patients pay a higher proportion of total costs have so far been made. |
| | |
Authors:
|
H Redwood |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: PharmacoEconomics Volume: 6 Suppl 1 ISSN: 1170-7690 ISO Abbreviation: Pharmacoeconomics Publication Date: 1994 |
Date Detail:
|
Created Date: 1995-11-29 Completed Date: 1995-11-29 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 9212404 Medline TA: Pharmacoeconomics Country: NEW ZEALAND |
Other Details:
|
Languages: eng Pagination: 3-10 Citation Subset: T |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Budgets Drug Costs / legislation & jurisprudence, trends* European Union Financing, Government / legislation & jurisprudence, trends Humans Insurance, Health, Reimbursement / legislation & jurisprudence, trends* Public Policy* |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Major technology issues in surgical data collection.
Next Document: Pricing and reimbursement of pharmaceuticals in Sweden.